What is the 13F Pro Quality Score for TRDA?

13F Pro ranks Entrada Therapeutics, Inc. (TRDA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TRDA's current score at https://13fpro.ai/research/TRDA (free sign-up required for the full ranking).

Which hedge funds own the most TRDA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of TRDA include BAKER BROS. ADVISORS, 5AM Venture Management,, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/TRDA as soon as new 13F filings post.

Where does 13F Pro source TRDA data?

All Entrada Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Entrada Therapeutics, Inc. files with the SEC under CIK 1689375. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TRDA in?

Entrada Therapeutics, Inc. (TRDA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is TRDA research updated on 13F Pro?

TRDA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Entrada Therapeutics, Inc.(TRDA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1689375 TRDA stock profile & AI dashboard →

13F Pro Quality Score

8.5/100

Rank #2,825 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

0.6/100

Profitability

3.2/100

Balance Sheet

5.2/100

Earnings Quality

30.0/100

Free Cash Flow

3.0/100

Institutional Flow

78.3/100

Revenue Scale

6.2/100

Dilution Risk

3.7/100

TRDA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Entrada Therapeutics, Inc. (TRDA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TRDA at 8.5/100 on a 32-signal composite quality model, placing it at rank #2,825 of 2,879 stocks — the bottom half of the AI-ranked universe. TRDA scores in the top quartile across institutional flow (78.3). Areas of concern include revenue growth (0.6) and free cash flow (3.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Entrada Therapeutics, Inc. reports quarterly revenue of $875.0K, net income of $-39.7M, free cash flow of $-41.7M. Top institutional holders of TRDA by reported 13-F value include BAKER BROS. ADVISORS, 5AM Venture Management,, BlackRock,, based on the most recent SEC filings. TRDA trades on the Nasdaq exchange and files with the SEC under CIK 1689375. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TRDA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Entrada Therapeutics, Inc. directly from SEC EDGAR. Entrada Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 6 and 65 since 2024, currently 8.5 — a declining long-term trajectory across 44 quarterly and live scoring snapshots.

Revenue

Q1 2026

$875.0K

Net Income

Q1 2026

$-39.7M

Free Cash Flow

Q1 2026

$-41.7M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-87.9% YoY

$25.4MFY 2025

FY22 —FY23 $129.0MFY24 $210.8MFY25 $25.4M

Net Income

-319.0% YoY

$-143.8MFY 2025

FY22 $-94.6MFY23 $-6.7MFY24 $65.6MFY25 $-143.8M

Operating Income

-435.9% YoY

$-157.9MFY 2025

FY22 $-97.2MFY23 $-3.2MFY24 $47.0MFY25 $-157.9M

EPS (Diluted)

-306.5% YoY

$-3.47FY 2025

FY22 $-3.02FY23 $-0.20FY24 $1.68FY25 $-3.47

Total Assets

-28.3% YoY

$377.4MFY 2025

FY22 $252.1MFY23 $469.2MFY24 $526.3MFY25 $377.4M

Op. Cash Flow

-209.2% YoY

$-128.5MFY 2025

FY22 $-93.8MFY23 $139.8MFY24 $-41.6MFY25 $-128.5M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$25.4M -87.9%	$210.8M +63.4%	$129.0M	—	—	—
Net Income	$-143.8M -319.0%	$65.6M +1081.7%	$-6.7M +92.9%	$-94.6M -84.9%	$-51.2M -92.9%	$-26.5M
Operating Income	$-157.9M -435.9%	$47.0M +1586.7%	$-3.2M +96.7%	$-97.2M -90.2%	$-51.1M -91.7%	$-26.7M
EPS (Diluted)	$-3.47 -306.5%	$1.68 +940.0%	$-0.20 +93.4%	$-3.02 +63.0%	$-8.16 +66.0%	$-24.00
Total Assets	$377.4M -28.3%	$526.3M +12.2%	$469.2M +86.1%	$252.1M -17.6%	$305.8M +602.6%	$43.5M
Operating Cash Flow	$-128.5M -209.2%	$-41.6M -129.7%	$139.8M +249.1%	$-93.8M -84.4%	$-50.9M -98.9%	$-25.6M

AI Insight: TRDA Financial Trends

Revenue collapsed 99% from $95M in Q2 2024 to $1M in Q1 2026 while quarterly losses persist at $40M+.

• Revenue plummeted from $95M in Q2 2024 to $1M in Q1 2026, a 99% decline over seven quarters.

• Operating losses stabilized around $42-47M per quarter since Q2 2025 after earlier volatility.

• Equity base eroded from $430M in Q2 2024 to $271M in Q1 2026, declining $159M over seven quarters.

⚠ Operating cash outflows worsened to $42M in Q1 2026, the highest quarterly burn in the dataset.

⚠ Revenue concentration risk evident from Q2 2024's $95M spike followed by sustained low single-digit millions.

AI Insight: TRDA Ratio Trends

Entrada's returns have deteriorated sharply, with ROIC falling from 49.7% in Q2 2024 to -62.5% in Q1 2026.

• ROIC collapsed from 49.7% in Q2 2024 to -62.5% in Q1 2026, reflecting seven consecutive quarters of decline.

• ROA dropped from 37.8% in Q2 2024 to -47.3% in Q1 2026, indicating deteriorating asset efficiency.

• Operating margin swung from 56.4% in Q2 2024 to -106.0% in Q1 2025 before data gaps emerged.

⚠ Missing operating margin and net profit margin data in recent quarters limits visibility into operational performance.

⚠ All profitability metrics remain deeply negative with TTM ROIC at -65.9%, suggesting ongoing cash burn.

Get alerted when TRDA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Entrada Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TRDA

BAKER BROS. ADVISORS LP
$64.0M5,072,730 sh
5AM Venture Management, LLC
$51.2M4,056,379 sh
BlackRock, Inc.
$29.8M2,358,793 sh
TCG Crossover Management, LLC
$28.9M2,287,500 sh
Merck & Co., Inc.
$22.0M1,739,768 sh
VANGUARD CAPITAL MANAGEMENT LLC
$15.9M1,256,013 sh
WELLINGTON MANAGEMENT GROUP LLP
$13.1M1,034,782 sh
StepStone Group LP
$9.6M761,277 sh
GEODE CAPITAL MANAGEMENT, LLC
$8.4M667,347 sh
STATE STREET CORP
$6.7M533,798 sh

Fund	Value	Shares
BAKER BROS. ADVISORS LP	$64.0M	5,072,730
5AM Venture Management, LLC	$51.2M	4,056,379
BlackRock, Inc.	$29.8M	2,358,793
TCG Crossover Management, LLC	$28.9M	2,287,500
Merck & Co., Inc.	$22.0M	1,739,768
VANGUARD CAPITAL MANAGEMENT LLC	$15.9M	1,256,013
WELLINGTON MANAGEMENT GROUP LLP	$13.1M	1,034,782
StepStone Group LP	$9.6M	761,277
GEODE CAPITAL MANAGEMENT, LLC	$8.4M	667,347
STATE STREET CORP	$6.7M	533,798

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TRDA on your watchlist

Track score changes the day Entrada Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TRDA a good stock to buy?

13F Pro's AI-powered analysis of Entrada Therapeutics, Inc. (TRDA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TRDA are available on the TRDA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own TRDA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TRDA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Entrada Therapeutics, Inc.'s investment landscape.